Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Phyto42 currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to a distinct examiner, MOREAU, NASHARA LOUISE, who is also the busiest examiner for the portfolio. The prosecution activity is concentrated within a distinct art unit, indicating a highly focused examination path for the company's current filings.
Practitioners should note that the presence of 1 distinct examiner and art unit suggests a narrow technical scope for the pending portfolio. Because MOREAU, NASHARA LOUISE handles the active matter, the outcome of this specific case will define the current success rate for the portfolio in this technology area. The concentration in the assigned art unit simplifies the monitoring of examiner trends and procedural norms for the applicant. This streamlined structure allows for a direct engagement strategy with the assigned examiner, who manages the entirety of the company's pending workload. The alignment of these figures reflects a consolidated approach to intellectual property management at this stage. By focusing on the specific preferences and historical data of the assigned official, the applicant can optimize their response strategy for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 66.7% | -80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18238641 | COMPOSITION FOR PATTERN RECOGNITION BASED TARGETING AND ACTIVATING AN INNATE IMMUNE RESPONSE | MOREAU, NASHARA LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18238641 | COMPOSITION FOR PATTERN RECOGNITION BASED TARGETING AND ACTIVATING AN INNATE IMMUNE RESPONSE | MOREAU, NASHARA LOUISE | 1655 | §101§103§112 | Non-Final OA | — | Pending | Aug 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPhyto42 has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nashara Louise Moreau has the most, with 1 of Phyto42's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
